



Company Contact - Jim Dorsey
BioClinica, Inc.
267-757-3040

Investor Contact – Michael Porter
Financial Media- Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

FOR IMMEDIATE RELEASE

BIOCLINICA, INC. TO PRESENT AT THE UBS 22nd ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE ON FEBRUARY 7, 2012 IN NEW YORK

NEWTOWN, PA, January 26, 2012 – BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, announced that Mark L. Weinstein, President and Chief Executive Officer will be presenting at the UBS 22nd Annual Global Healthcare Services Conference in New York City on Tuesday, February 7, 2012 at 4:00 p.m. EST.

Mr. Weinstein will be discussing an overview of BioClinica, its business strategy and financial performance.

The Company will provide a live audio broadcast of the presentation. To access this presentation, listeners should go to the Investor Relations section of the Company's website, and access the following link, approximately 15 minutes prior to the event to register and download any necessary software:

<http://www.bioclinica.com/investor-events/>

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#####